The studies [97, 98] investigated that the treatments combining Gal-1 inhibition with other cancer therapies showed that anginex (a novel angiogenesis inhibitor) could improve radiochemotherapy outcomes in transgenic model of aggressive breast cancer and A squamous cell (SCCVII) xenograft tumor mouse model, but the detailed mechanism involved was still in research. Here, LGALS1 is linked to breast cancer.